Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients | BMC Pharmacology and Toxicology | Full Text

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients | BMC Pharmacology and Toxicology | Full Text

Hormonal status affects plasma exposure of tamoxifen and its main metabolites in tamoxifen-treated breast cancer patients

Tamoxifen is considered a prodrug of its active metabolite endoxifen, which is dependent on the CYP2D6 and CYP3A enzymes. Tamoxifen pharmacokinetic variability influences endoxifen exposure and, consequently, ...

Authors:João Paulo Bianchi Ximenez, Jurandyr Moreira de Andrade, Maria Paula Marques, Eduardo Barbosa Coelho, Guilherme Suarez-Kurtz and Vera Lucia Lanchote

Citation:BMC Pharmacology and Toxicology 2019 20(Suppl 1):81

Content type:Research

Published on: 19 December 2019

This article is part of a Supplement: Volume 20 Supplement 1

• ViewFull Text
 
• ViewPDF